News

Print Version

Resverlogix Announces Participation in Upcoming Conferences

CALGARY, Alberta, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. (Resverlogix or the "Company") (TSX:RVX) is pleased to announce the Companys participation in the following upcoming industry conferences.


American Society of Nephrology ASN 2017 Annual Meeting

Location:New Orleans, LA.
Date:November 3rd, 2017
Poster 1:
Analysis of the Plasma Proteome Reveals Dysregulation of Molecular Pathways in Patients with Stage 4 Chronic Kidney Disease
Presentation Time:10:00am - 12:00pm CT
Date:November 4th, 2017
Poster 2:

Apabetalone (RVX-208) Impacts Key Markers and Pathways Associated with Chronic Kidney Disease in Patients with Severe Renal Impairment

Presentation Time:
10:00am - 12:00pm CT
Meeting Link: LINK


BIO-Europe 2017

Location:Berlin, Germany.
Date:November 7th, 2017
Presentation Time:4:45pm CEST
Presenting:Mr. Donald McCaffrey, President and Chief Executive Officer
Conference Link:LINK


American Heart Association AHA Scientific Sessions 2017

Location:Anaheim, CA
Date:November 13th, 2017
Poster:
Apabetalone Downregulates Factors That Promote Vascular Calcification and Contribute to Cardiovascular Events
Presentation Time:10:30am PT
Meeting Link:LINK


About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial designed to evaluate biomarker changes and safety parameters in up to 30 patients with end-stage renal disease treated with hemodialysis.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

For further information please visit www.resverlogix.com.

Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog

For further information please contact:

Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252


Back to News